Immune thrombocytopenia induced by nivolumab in a patient with non-small cell lung cancer-Reference-Cited by-同舟云学术

Immune thrombocytopenia induced by nivolumab in a patient with non-small cell lung cancer

Published:2019 Issue: Volume:28 Page:100871
ISSN:2213-0071
Container-title:Respiratory Medicine Case Reports
language:en
Short-container-title:Respiratory Medicine Case Reports

Author:

Mori Hidenori,Sakai Chizuru,Iwai Masamichi,Sasaki Yuka,Gomyo Takenobu,Toyoshi Sayaka,Kaito Daizo,Yanase Komei,Ito Fumitaka,Endo Junki,Funaguchi Norihiko,Ohno Yasushi,Minatoguchi Shinya

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference10 articles.

1. Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer: results from the CA209-003 study;Gettinger;J. Clin. Oncol.,2018

2. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy;Hofmann;Eur. J. Cancer,2016

3. Safety and tolerability of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: a meta-analysis of randomized controlled trials;Luo;J. Cancer Res. Clin. Oncol.,2018

4. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy;Shiuan;J. Immunother. Cancer,2017

5. Nivolumab-induced severe pancytopenia in a patient with lung adenocarcinoma;Tokumo;Lung Cancer,2018

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PD-1/PD-L1 inhibitor-induced immune thrombocytopenia: A pharmacovigilance study and systematic review;International Immunopharmacology;2024-03

2. High levels of PD-L1 on platelets of NSCLC patients contributes to the pharmacological activity of Atezolizumab;Biomedicine & Pharmacotherapy;2023-12

3. Hematological toxicities of immune checkpoint inhibitors and the impact of blood transfusion and its microbiome on therapeutic efficacy and recipient’s safety and survival outcome:A systematic narrative appraisal of where we are now!;Transfusion and Apheresis Science;2023-04

4. Immune thrombocytopenic purpura caused by combination therapy of atezolizumab and bevacizumab for unresectable hepatocellular carcinoma: A case presentation;Kanzo;2022-07-01

5. Immune Thrombocytopenia Induced by Immune Checkpoint Inhibitrs in Lung Cancer: Case Report and Literature Review;Frontiers in Immunology;2021-12-09